TheStreet downgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a c- rating to a d rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports.
Several other equities analysts have also issued reports on AEZS. Zacks Investment Research lowered AEterna Zentaris from a buy rating to a hold rating in a report on Friday, March 15th. ValuEngine lowered AEterna Zentaris from a buy rating to a hold rating in a report on Wednesday, March 27th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $3.17.
Shares of AEterna Zentaris stock opened at $3.02 on Thursday. AEterna Zentaris has a one year low of $1.29 and a one year high of $5.57. The stock has a market capitalization of $45.21 million, a P/E ratio of 12.08 and a beta of 1.34.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.18). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $4.20 million. AEterna Zentaris had a negative net margin of 666.76% and a negative return on equity of 328.95%. On average, equities analysts anticipate that AEterna Zentaris will post 1.71 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in shares of AEterna Zentaris in the fourth quarter valued at approximately $30,000. O Shaughnessy Asset Management LLC bought a new position in shares of AEterna Zentaris in the fourth quarter valued at approximately $66,000. Acadian Asset Management LLC grew its holdings in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 9,640 shares in the last quarter. Virtu Financial LLC bought a new position in shares of AEterna Zentaris in the first quarter valued at approximately $179,000. Finally, Renaissance Technologies LLC grew its holdings in shares of AEterna Zentaris by 232.8% in the first quarter. Renaissance Technologies LLC now owns 110,078 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 77,000 shares in the last quarter. 13.67% of the stock is owned by institutional investors.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
See Also: Why Invest in Dividend Achievers?
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.